Louisiana Department of Health and Hospitals (DHH) Medicaid Pharmaceutical and Therapeutic (P&T) Committee Meeting Minutes

April 30, 2014
# Table of Contents

Table of Contents

1.0 Meeting Overview

1.1 Call to Order

1.2 Parliamentary Business

1.2.1 Introduction of Members and Roll Call

1.2.2 Approval of Minutes

1.3 Reports

1.3.1 Background

1.3.2 Code of Ethics

1.3.3 DrH Report

1.4 New Business

1.4.1 Public Testimony

2.0 Therapeutic Class Reviews

2.1 Analgesics, Narcotics Long

2.2 Analgesics, Narcotics Short

2.3 Androgenic Agents

2.4 Angiotensin Modulator Combos

2.5 Angiotensin Modulators

2.6 Antibiotics, GI

2.7 Antibiotics, Inhaled

2.8 Antibiotics, Topical

2.9 Antibiotics, Vaginal

2.10 Anticoagulants

2.11 Antiemetics/Antivertigo Agents

2.12 Antifungals, Oral

2.13 Antifungals, Topical

2.14 Antimigraine Agents, Triptans

2.15 Antiparasitics, Topical

2.16 Antivirals, Topical

2.17 Beta Blockers

2.18 Bladder Relaxant Preparations

2.19 Bone Resorption Suppression and Related Agents

2.20 BPH Treatments

2.21 Calcium Channel Blockers

2.22 Cephalosporins and Related Antibiotics

2.23 Erythropoiesis Stimulating Proteins

---

Page 2 | Louisiana DHH Medicaid P&T Committee Meeting Minutes
2.24  Fluoroquinolones, Oral .......................................................... 16
2.25  Growth Hormone ................................................................. 16
2.26  Hepatitis C ............................................................................. 16
2.27  Hypoglycemics, Incretin Mimetics and Enhancers .......... 17
2.28  Hypoglycemics, Insulins and Related ......................... 17
2.29  Hypoglycemics, Meglitinides ............................................ 18
2.30  Hypoglycemics, SGLT2 (new class for review) .......... 18
2.31  Hypoglycemics, TZD ............................................................ 18
2.32  Lincomates/Oxazolidinones/Streptogramins ................. 18
2.33  Lipotropics, Other ................................................................. 19
2.34  Lipotropics, Statins ............................................................... 19
2.35  Macrolides/Ketolides ............................................................ 19
2.36  Multiple Sclerosis Agents .................................................... 20
2.37  Opiate Dependence Treatments .......................................... 20
2.38  PAH Agents, Oral and Inhaled ........................................... 20
2.39  Pancreatic Enzymes ............................................................... 21
2.40  Phosphate Binders ................................................................. 21
2.41  Pituitary Suppressive Agents, LHRH ................................. 21
2.42  Platelet Aggregation Inhibitors ............................................. 22
2.43  Proton Pump Inhibitors .......................................................... 22
2.44  Skeletal Muscle Relaxants .................................................... 22
2.45  Tetracyclines ........................................................................ 23
2.46  Ulcerative Colitis ................................................................. 23
3.0  Single Drugs ........................................................................ 24
3.1  Antidepressants Other, Brintellix and Fetzima .................. 24
3.2  Antipsychotics, Versadol ....................................................... 24
3.3  Cytokine and CAM Antagonists, Actemra syringe ............ 24
3.4  Glucocorticoid Inhaled, Aerospan ...................................... 25
3.5  NSAIDs, Zovoxel .................................................................. 25
4.0  Next Steps ............................................................................ 25
4.1  Next Meeting Date ................................................................. 25
5.0  Adjournment ....................................................................... 25

MagellanRx

Louisiana DHH Medicaid P&T Committee Meeting Minutes | Page 3
## Meeting Overview

**Subject:** Louisiana Department of Health and Hospitals (DHH)  
Medicaid Pharmaceutical and Therapeutic Committee Meeting (P&T)

**Location:**  
628 North Fourth Street  
Baton Rouge, LA 70802  
Bienville Building  
Room 3118

**Date:** April 30, 2014

**Members Present:**  
- Brian Boulmayay, M.D.  
- Jill Comeau, Pharm. D.  
- Jeffrey Deyo, MD  
- Rebekah Gee, MD  
- Amy Givler, MD  
- Martha Harris, Pharm. D.  
- James Lu, MD  
- Marty R. McKay, RPh  
- Edward Mader, MD  
- Melvin Murrill, MD  
- Ben Orlando, Pharm. D.  
- Sukanthini Subbiah, MD  
- Mohammad Suleman, MD  
- Neil Wolfson, MD

**DHH Pharmacy Program Staff Present:**  
- Melwyn Wendt, Pharm. D.  
- Germaine Becks-Moody, PhD, BHSP Program Manager  
- Rebecca Hebert  
- Paul Knecht, Pharm. D.  
- Evonna ‘Sue’ Fontenot, RPh  
- Mary Wolfe  
- Kim Sullivan

**Contractors Present:**  
- Julie Pritchard, PharmD, Magellan Medicaid Administration  
- Jennifer Picket, Certified Court Reporter

**Others Present:** Presenters are listed in the minutes and sign-in sheets and others in attendance from DHH, Bureau of Health Services Financing, Pharmacy Benefits Section upon request.
1.1 Call to Order

Marty R. McKay, Chairman, called the meeting to order at 9:39 a.m.

1.2 Parliamentary Business

1.2.1 Introduction of Members and Roll Call

Committee members and staff introduced themselves.

1.2.2 Approval of Minutes

Mr. McKay asked for a motion to approve the minutes. Dr. Murrill offered a motion to approve the minutes. Mr. Orlando seconded the motion, which passed.

1.3 Reports

1.3.1 Background

Ms. Sullivan provided the background of forming the committee, which was established under Louisiana revised statute 45:153.3. The purpose of the committee is to develop a Preferred Drug List with no prior authorization, make recommendations for additions and deletions for the Preferred Drug List, and to advise the Secretary of DHH on policy recommendations related to the administration of the Medicaid Pharmacy program. The committee consists of 21 members appointed by the Governor and confirmed by the Senate. The committee must abide by the code of governmental ethics. At this time, the bylaws are to stay the same and there are no statutory updates. Proposed bylaws will be sent out two weeks prior to the next meeting; members can vote to amend bylaws.

1.3.2 Code of Ethics

Ms. Sullivan went over the code of ethics. Members are bound by the governmental code of ethics. Section 115 prohibits a public servant from soliciting or accepting anything of economic value from any person who has contractual business or a financial relationship with the agency. Committee members cannot receive honorariums, reimbursements, or compensation of any kind, including grants from pharmaceutical companies that have items on the Preferred Drug List or matters before the committee. A P&T Committee member can attend conferences and seminars sponsored by drug companies that have items on the Preferred List or matters before the P&T committee, as long as the member
pays their own expenses for the trip. Committee members who are employees of a university cannot solicit grants on behalf of the university. Members do not have to file financial disclosure statements. If anyone has personal ethical questions, please visit the Board of Ethics at www.ethics.state.la.us or contact Kim Sullivan at Kimberly.sullivan@la.gov.

1.3.3 DHH Report

Melwyn Wendt from DHH provides report. Ms. Wendt called committee members attention to the packet they received with the Prior Authorization (PA) monthly report. Also in the packet was the Preferred Drug List from the November 06, 2013 meeting.

1.4 New Business

Dr. Pritchard provided an overview of the TOP$ program to the committee.

1.4.1 Public Testimony

In accordance with state law and the P&T Committee’s Bylaws, the following provided public testimony or answered questions raised by the Committee during the Committee’s review of Therapeutic Classes.

<table>
<thead>
<tr>
<th>Presenter</th>
<th>Representing</th>
<th>Drug/Issue</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr. Quynhehau Doan</td>
<td>AbbVie</td>
<td>Androgel</td>
</tr>
<tr>
<td>Ruth Haile-Mesale</td>
<td>Daiichi Sankyo</td>
<td>Tribenzor</td>
</tr>
<tr>
<td>Ruth Haile-Mesale</td>
<td>Daiichi Sankyo</td>
<td>Benicar</td>
</tr>
<tr>
<td>Michelle Kliebert</td>
<td>Gilead</td>
<td>Cuyston</td>
</tr>
<tr>
<td>Julia Compton</td>
<td>Novartis</td>
<td>Tobi Podhaler</td>
</tr>
<tr>
<td>Dr. Scott Davis</td>
<td>Tulane CF Center</td>
<td>Antibiotics, Inhaled</td>
</tr>
<tr>
<td>Ann McMahon Wicker</td>
<td>Pfizer</td>
<td>Genotropin</td>
</tr>
<tr>
<td>Eric</td>
<td>Novartis</td>
<td>Nutropin</td>
</tr>
<tr>
<td>Michelle Kliebert</td>
<td>Gilead</td>
<td>Sovaldi</td>
</tr>
<tr>
<td>Brian Macomson</td>
<td>Janssen</td>
<td>Olysio</td>
</tr>
<tr>
<td>Fran Kaiser</td>
<td>Merck</td>
<td>Vietrelia</td>
</tr>
<tr>
<td>Kathy Todd Wilson</td>
<td>BMS</td>
<td>Onglyza, Kombiglyze, Bydureon</td>
</tr>
<tr>
<td>Brian Macomson</td>
<td>Janssen</td>
<td>Invokana</td>
</tr>
<tr>
<td>Kathy Todd Wilson</td>
<td>BMS</td>
<td>Farxiga</td>
</tr>
<tr>
<td>Presenter</td>
<td>Representing</td>
<td>Drug/issue</td>
</tr>
<tr>
<td>-----------------</td>
<td>--------------</td>
<td>----------------</td>
</tr>
<tr>
<td>Fran Kaiser</td>
<td>Merck</td>
<td>Zetia, Zocor</td>
</tr>
<tr>
<td>Rebecca Martin</td>
<td>Aegerion</td>
<td>Juxtapid</td>
</tr>
<tr>
<td>Michelle Kliebert</td>
<td>Gilead</td>
<td>Gilenya</td>
</tr>
<tr>
<td>Steve Bowman</td>
<td>Teva</td>
<td>Copaxone</td>
</tr>
<tr>
<td>Richard Guston</td>
<td>Orexo</td>
<td>Zubsolv</td>
</tr>
<tr>
<td>Kristen Pazernac</td>
<td>AstraZeneca</td>
<td>Brilinta</td>
</tr>
<tr>
<td>Tyrone Bane</td>
<td>Forrest Labs</td>
<td>Petzima</td>
</tr>
<tr>
<td>Parish Pope</td>
<td>Jazz</td>
<td>Versacloz</td>
</tr>
</tbody>
</table>
2.0 Therapeutic Class Reviews

Forty-six (46) therapeutic classes were reviewed. Mr. McKay explained the Committee’s review procedures. Monograph summaries were sent to the Committee prior to the meeting. Public comment was received for each therapeutic class prior to Committee discussion and action in accordance with state law and the P&T Committees Bylaws. Committee proceedings follow.

2.1 Analgesics, Narcotics Long

Dr. Givler made the motion to accept; Dr. Wolfson seconded the motion. After discussion, a roll call vote was taken and the original motion passed with all in favor.

Committee Recommendations for the PDL

- Fentanyl transdermal
- Methadone soln, tab, ODT, conc
- Morphine ER tab

2.2 Analgesics, Narcotics Short

Dr. Harris made a motion to accept the recommendations; Mr. McKay seconded the motion. Roll call was taken and the motion passed with all in favor. (Oxycodone tablets were voted to be removed from the PDL, only the capsules are preferred).

Committee Recommendations for the PDL

- Butal/caff/APAP/cod
- Codeine/APAP elix. tab
- Hydrocodone/APAP soln, tab
- Hydrocodone/IBU
- Morphine soln, IR tab
- Oxycodone cap, soln
- Oxycodone/APAP cap, tab
- Tramadol
- Tramadol/APAP
2.3 Androgenic Agents

Dr. Gee made the motion to make the whole class require a PA; Dr. Wolfson seconded the motion. After discussion, it was decided to remove this class from the P&T review process altogether and PA the entire class. Roll call was taken and the motion passed with one opposed. Dr. Doan from AbbVie spoke on Androgel.

Committee Recommendations for the PDL

- None, all drugs require PA, class no longer to be reviewed in the P&T process.

2.4 Angiotensin Modulator Combos

Dr. Wolfson made the motion to accept; Dr. Sulemon seconded the motion. After discussion and a speaker on Tribenzor, Ruth Haile-Meskale spoke, roll call was taken and the original motion passed with a unanimous vote.

Committee Recommendations for the PDL

- Amlodipine/benazepril
- Azor
- Exforge
- Exforge HCT

2.5 Angiotensin Modulators

Dr. Wolfson made the motion to accept; Mr. Orlando seconded the motion. After one pharmaceutical manufacturer’s requests to make presentations, Ruth Meskale on Benicar, roll call was taken and the original motion passed with a unanimous vote.

Committee Recommendations for the PDL

- Benazepril/HCTZ and benazepril
- Captopril/HCTZ and captopril
- Diovan
- Enalapril/HCTZ and enalapril
- Irbesartan/HCTZ and irbesartan
- Lisinopril HCTZ and lisinopril
- Losartan HCTZ and losartan
• Ramipril
• Valsartan HCTZ

2.6 Antibiotics, GI

Dr. Sulemon made the motion to accept; Dr. Givler seconded the motion. After discussion and no pharmaceutical manufacturers’ requests to make presentations, the motion passed with a unanimous vote.

Committee Recommendations for the PDL

• Metronidazole tab
• Neomycin
• Vancocin

2.7 Antibiotics, Inhaled

Dr. Suleman made the motion to accept; Dr. Wolfson seconded the motion. After discussion and pharmaceutical manufacturers’ presentation by Michelle Kliebert from Gilead on Cayston and Julia Compton pharmacist with Novartis on Tobi Podhaler, and Dr. Scott Davis, director for the CF Center at Tulane, roll call was taken and the motion passed.

Committee Recommendations for the PDL

• Bethkis
• Tobi Podhaler

2.8 Antibiotics, Topical

Mr. Orlando made the motion to accept; Dr. Givler seconded the motion. There was no discussion and no speakers. Roll call was taken and the motion passed.

Committee Recommendations for the PDL

• Gentamicin oint and cream
• Mupirocin oint
2.9 **Antibiotics, Vaginal**

Mr. Orlando made the motion to accept; Dr. Suleman seconded the motion. After no pharmaceutical manufacturers' requests to make presentations, roll call was taken and the original motion passed with a unanimous vote.

**Committee Recommendations for the PDL**

- Cleocin Ovules
- Metrogel Vaginal

2.10 **Anticoagulants**

Dr. Suleman made the motion to accept; Dr. Wolfson seconded the motion. There were no speakers, roll call was taken and the motion carried to accept the proposed list unanimously.

**Committee Recommendations for the PDL**

- Injectable
  - Fragmin disp syr and vial
  - Lovenox syr and vial
- Oral
  - Eliquis
  - Pradaxa
  - Warfarin
  - Xarelto

2.11 **Antiemetics/Antivertigo Agents**

Dr. Suleman made the motion to accept; Dr. Wolfson seconded the motion. There were no speakers, roll call was taken and the motion passed.

**Committee Recommendations for the PDL**

- Emend tabs and pack
- Meclizine
- Metoclopramide vial, syr, tab, soln
- Ondansetron disp syr, vial, ODT, tab, soln
• Phenergan amp
• Prochlorperazine oral and inj
• Promethazine disp syr, vial, syrup, tab, amp, rectal
• Transderm-Scop
• Trimethobenzamide oral and IM

2.12 Antifungals, Oral

Dr. Wolfson made the motion to accept; Mr. Orlando seconded the motion. Dr. Givler amended the motion to include removing ketoconazole from the PDL due to risk of hepatotoxicity. After no pharmaceutical manufacturers’ requests to make presentations, roll call was taken and the original motion passed with a unanimous vote.

Committee Recommendations for the PDL

• Clotrimazole troche
• Fluconazole tab, susp
• Griseofulvin susp
• Gris-Peg
• Nystatin susp, tab
• Terbinafine oral

2.13 Antifungals, Topical

Dr. Suleman made the motion to accept; Dr. Wolfson seconded the motion. There were no speakers, roll call was taken and the amended motion passed with a unanimous vote.

Committee Recommendations for the PDL

• Clotrimazole soln, cream
• Clotrimazole/betamethasone cream
• Econazole
• Ketoconazole cream and shampoo
• Nystatin cream, oint, pwd
• Nystatin/triamcinolone oint, cream
2.14 **Antimigraine Agents, Triptans**

Mr. Orlando made the motion to accept; Dr. Mader seconded the motion. There were no speakers and no discussion, roll call was taken and the original motion passed with a unanimous vote.

**Committee Recommendations for the PDL**

- Imitrex nasal, kit, vial
- Relpax oral
- Rizatriptan tab and ODT
- Sumatriptan oral

2.15 **Antiparasitics, Topical**

Dr. Harris made the motion to accept; Dr. Wolfson seconded the motion. Roll call was taken and the original motion passed with a unanimous vote.

**Committee Recommendations for the PDL**

- Natroba
- Permethrin cream
- Sklice
- Ulefsia

2.16 **Antivirals, Topical**

Mr. Orlando made the motion to accept; Dr. Wolfson seconded the motion. Roll call was taken and the original motion passed with a unanimous vote.

**Committee Recommendations for the PDL**

- Acyclovir oint
- Denavir

2.17 **Beta Blockers**

Dr. Wolfson made the motion to accept; Dr. Suleman seconded the motion. After much discussion, roll call was taken and the motion passed with a unanimous vote.
Committee Recommendations for the PDL

- Atenolol
- Atenolol/chlorthalidone
- Bisoprolol/HCTZ
- Bystolic
- Carvedilol
- Labetalol
- Metoprolol
- Propranolol tab, soln, ER, HCTZ
- Sotalol
- Toprol XL

2.18  Bladder Relaxant Preparations

Dr. Wolfson moved to accept the list: Mr. Orlando seconded. There was some discussion, roll was taken and the motion with the amendment passed unanimously.

Committee Recommendations for the PDL

- Oxybutynin syrup, tab, ER
- Toviaz
- Vesicare

2.19  Bone Resorption Suppression and Related Agents

Dr. Wolfson made the motion to accept: Dr. Harris seconded the motion. With no discussion and no speakers, roll call was taken and the original motion passed with a unanimous vote.

Committee Recommendations for the PDL

- Alendronate tabs
- Fortical nasal
2.20 BPH Treatments

Dr. Suleman moved to accept; Dr. Wolfson seconded. After a brief discussion, roll call was taken and the motion passed unanimously.

Committee Recommendations for the PDL

- Alfuzosin
- Doxazosin
- Finasteride
- Tamsulosin
- Terazosin

2.21 Calcium Channel Blockers

Mr. Orlando made the motion to accept; Dr. Wolfson seconded the motion. Roll call was taken and the original motion passed with a unanimous vote.

Committee Recommendations for the PDL

- Amlodipine
- Diltiazem tab and ER capsule
- Nifedipine and ER
- Verapamil tab and ER caps and tabs

2.22 Cephalosporins and Related Antibiotics

Dr. Suleman made the motion to accept; Dr. Wolfson seconded the motion. After no pharmaceutical manufacturers’ requests to make presentations, roll call was taken and the original motion passed with a unanimous vote.

Committee Recommendations for the PDL

- Amox/clav tab, susp, chew
- Ceftadroxil caps
- Cefdinir susp
- Cefprozil tab, susp
- Cefuroxime tab
- Cephalexin caps, susp, tab
• Suprax caps, susp, chew

2.23 Erythropoiesis Stimulating Proteins

Dr. Suleman made the motion to accept; Mr. Orlando seconded the motion. Roll call was taken and the original motion passed with a unanimous vote.

Committee Recommendations for the PDL

• Aranesp vial, disp syr
• Procrit

2.24 Flouroquinolones, Oral

Dr. Wolfson made the motion to accept; Mr. Orlando seconded the motion. After no pharmaceutical manufacturers’ requests to make presentations, roll call was taken and the original motion passed with a unanimous vote.

Committee Recommendations for the PDL

• Ciprofloxacin tab
• Levofloxacin tab

2.25 Growth Hormone

Mr. Orlando made the motion to accept; Dr. Harris seconded the motion. Ann McMahon Wicker from Pfizer spoke on Genotropin, Eric spoke for Novartis on Nutropin, roll call was taken and the motion passed.

Committee Recommendations for the PDL

• Norditropin pen
• Nutropin AQ cartridge

2.26 Hepatitis C

Dr. Wolfson made the motion to accept; Dr. Suleman seconded the motion. After much discussion and Michelle Kleibert from Gilead speaking on Sovaldi, Brian Macomson from Janssen speaking for Olysio, and Fran Kaiser with Merck speaking on Victrelis, a motion was made to remove Incivek from the PDL. Roll call was taken and the motion passed with a unanimous vote.
Committee Recommendations for the PDL

- Pegasis vial, proclick, syr, kit
- Ribavirin tab
- Victrelis

2.27 Hypoglycemics, Incretin Mimetics and Enhancers

Dr. Suleman made the motion to accept; Dr. Givler seconded the motion. After much discussion and a motion to add Victoza and remove Byetta from the PDL, and Kathy Todd Wilson speaking for BMS on Onglyza and Kombiglyze and Bydureon, roll call was taken and the motion passed with a unanimous vote.

Committee Recommendations for the PDL

- Janumet & XR
- Januvia
- Jentaduo
- Tradjenta
- Bydureon
- Victoza

2.28 Hypoglycemics, Insulins and Related

Mr. Orlando made the motion to accept; Dr. Wolfson seconded the motion. There were no speakers. Roll call was taken and the original motion passed with a unanimous vote.

Committee Recommendations for the PDL

- Humalog vial, pen, cartridge
- Humalog Mix vial, pen
- Humulin 500 U/mL vial
- Humulin 70/30 OTC vial, pen
- Humulin OTC vial, pen
- Lantus Solostar pen
- Lantus vial
- Levemir pen, vial
- Novolin 70/30 OTC vial
2.29   Hypoglycemics, Meglitinides

Dr. Suleman made the motion to accept: Dr. Wolfson seconded the motion. After no pharmaceutical manufacturers’ requests to make presentations, roll call was taken and the original motion passed with a unanimous vote.

Committee Recommendations for the PDL

- Natiglinide
- Prandin

2.30   Hypoglycemics, SGLT2 (new class for review)

Mr. Orlando made the motion to accept: Dr. Wolfson seconded the motion. Brian Macomson, Janssen, spoke on Invokana and Kathy Todd Wilson from BMS spoke on Farxiga. Roll call was taken and the original motion passed with a unanimous vote.

Committee Recommendations for the PDL

None: both drugs in the class are non-preferred.

2.31   Hypoglycemics, TZD

Dr. Suleman made the motion to accept: Mr. Orlando seconded the motion. After no pharmaceutical manufacturers’ requests to make presentations, roll call was taken and the original motion passed with a unanimous vote.

Committee Recommendations for the PDL

- Pioglitazone

2.32   Lincosamides/oxazolidinones/Streptogramins

Mr. Orlando made a motion: Dr. Wolfson seconded the motion. After discussion and no presentation, roll call was taken and the motion passed.
Committee Recommendations for the PDL

- Clindamycin caps
- Clindamycin palmitate soln

2.33 Lipotropics, Other

Dr. Suleman made the motion to accept; Dr. Wolfson seconded the motion. Fran Kaiser from Merck spoke on Zocon and Zetia, then Rebecca Martin from Aegerion spoke on Juxtapid, roll call was taken and the original motion passed.

Committee Recommendations for the PDL

- Cholestyramine/sucrose and aspartame
- Colestipol tab
- Gemfibrozil
- Niacor
- Tricor
- Trilipix

2.34 Lipotropics, Statins

Dr. Suleman made the motion to accept; Dr. Wolfson seconded the motion. After much discussion, an amendment was made to non-prefer Pravastatin and to Prefer Crestor; roll call was taken and the motion passed.

Committee Recommendations for the PDL

- Atorvastatin
- Crestor
- Lovastatin
- Simvastatin

2.35 Macrolides/Ketolides

Dr. Wolfson made the motion to accept; Dr. Suleman seconded the motion. After no pharmaceutical manufacturers’ requests to make presentations and no discussion, roll call was taken and the original motion passed with a unanimous vote.
Committee Recommendations for the PDL

- Azithromycin tab, susp, packet
- Clarithromycin tab
- Erypred 400 susp
- Erytab

2.36 **Multiple Sclerosis Agents**

Dr. Suleman made the motion to accept; Dr. Wolfson seconded the motion. After Michelle Kliebert from Gilead spoke on Gilenya and Steve Bowman from Teva spoke on Copaxone and much discussion on the oral agents, roll call was taken and the motion passed.

Committee Recommendations for the PDL

- Avonex pen and vial
- Betaseron kit
- Copaxone syr kit (20mg/mL)
- Rebif
- Rebif Rebidose pen inj

2.37 **Opiate Dependence Treatments**

Dr. Suleman made the motion to accept; Dr. Wolfson seconded the motion. After Richard Guston from Orexo spoke on Zubravol, there was much discussion on the products and an amendment was made to non-prefer buprenorphine HCl, roll call was taken and the motion passed.

Committee Recommendations for the PDL

- Naltrexone
- Suboxone film

2.38 **PAH Agents, Oral and Inhaled**

Dr. Suleman made the motion to accept; Dr. Wolfson seconded the motion. After a lot of committee discussion and an amendment to Non-prefer Ventavis, roll call was taken and the motion passed.
Committee Recommendations for the PDL

- Letairis
- Sildenafil
- Tracleer

2.39    Pancreatic Enzymes

Mr. Orlando made the motion to accept; Dr. Wolfson seconded the motion. There was no speaker and no discussion. Motion passed unanimously.

Committee Recommendations for the PDL

- Creon
- Pancrelipase
- Zenpep

2.40    Phosphate Binders

Dr. Suleman made the motion to accept; Dr. Wolfson seconded the motion. There was no speaker and no discussion. Motion passed unanimously.

Committee Recommendations for the PDL

- Calcium acetate caps
- Eliphos
- Renagel

2.41    Pituitary Suppressive Agents, LHRH

Mr. Orlando made the motion to accept; Dr. Wolfson seconded the motion. There was no speaker and no discussion. Motion passed unanimously.

Committee Recommendations for the PDL

- Lupron Depot and kit
- Lupron Depot ped and kit
2.42 Platelet Aggregation Inhibitors

Mr. Orlando made the motion to accept: Dr. Wolfson seconded the motion. Kristen Pazenc with AstraZeneca spoke on Brilinta. There was no discussion and the motion passed unanimously.

Committee Recommendations for the PDL

- Aggrenox
- Clopidogrel
- Dipyridamole

2.43 Proton Pump Inhibitors

Mr. Orlando made the motion to accept: Dr. Wolfson seconded the motion. There was no speaker and no discussion. Motion passed unanimously.

Committee Recommendations for the PDL

- Omeprazole
- Pantoprazole
- Protonix susp

2.44 Skeletal Muscle Relaxants

Mr. Orlando made the motion to accept: Dr. Wolfson seconded the motion. There was no speaker and no discussion. Motion passed unanimously.

Committee Recommendations for the PDL

- Baclofen
- Chlorzoxazone
- Cyclobenzaprine
- Methocarbamol
- Tizanidine tabs
2.45 Tetracyclines

Dr. Suleman made the motion to accept; Dr. Wolfson seconded the motion. There was no speaker and no discussion. Motion passed unanimously.

Committee Recommendations for the PDL

- Doxycycline hyclate tab, caps
- Doxycycline monohydrate 100mg caps
- Minocycline caps
- Tetracycline

2.46 Ulcerative Colitis

Mr. Orlando made the motion to accept; Dr. Wolfson seconded the motion. There was no speaker and no discussion. Motion passed unanimously.

Committee Recommendations for the PDL

- Apriso
- Balsalazide
- Canasa rectal
- Sulfasalazine and DR
3.0 Single Drugs

The new drug reviews or single drug reviews are on products that have come to the market since the last review of the class. Ten (10) new drugs were reviewed and a recommendation was made. P&T Committee recommendations follow.

3.1 Antidepressants Other, Brintellix and Fetzima

Dr. Murrill made the motion to accept; Dr. Wolfson seconded the motion. After pharmaceutical manufacturers’ representative Tyrone Bane presented on Fetzima, roll call was taken and the original motion passed with a unanimous vote.

Committee Recommendations for the PDL

• None; both drugs are non-preferred.

3.2 Antipsychotics, Versacloz

Dr. Suleman made the motion to accept; Dr. Wolfson seconded the motion. After pharmaceutical manufacturers’ representative Parish Pope presented on Versacloz, roll call was taken and the original motion passed with a unanimous vote.

Committee Recommendations for the PDL

• Drug is non-preferred.

3.3 Cytokine and CAM Antagonists, Actemra syringe

Dr. Suleman made the motion to accept; Dr. Wolfson seconded the motion. There was no speaker and no discussion; roll call was taken and the original motion passed with a unanimous vote.

Committee Recommendations for the PDL

• Drug is non-preferred.
3.4 Glucocorticoid Inhaled, Aerospan

Dr. Suleman made the motion to accept; Dr. Wolfson seconded the motion. There was no speaker and no discussion; roll call was taken and the original motion passed with a unanimous vote.

Committee Recommendations for the PDL

- Drug is non-preferred

3.5 NSAIDs, Zovolex

Dr. Suleman made the motion to accept; Mr. Orlando seconded the motion. There was no speaker and no discussion; roll call was taken and the original motion passed with a unanimous vote.

Committee Recommendations for the PDL

- Drug is non-preferred

4.0 Next Steps

Therapy classes to be reviewed for the Fall 2014 meeting will be posted on the DHH Medicaid Pharmacy and Therapeutics Committee page as “Agenda.”

4.1 Next Meeting Date

The next committee meeting date is to be determined (TBD).

5.0 Adjournment

Dr. Murrill offered the motion to adjourn the meeting; Dr. Suleman seconds the motion. The meeting adjourned at 3:37 p.m.

Marty McKay, P&T Committee Chairman/Date